U.S. flag

An official website of the United States government

NM_000527.5(LDLR):c.1003G>C (p.Gly335Arg) AND Hypercholesterolemia, familial, 1

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Apr 28, 2023
Review status:
3 stars out of maximum of 4 stars
reviewed by expert panel
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003318667.1

Allele description [Variation Report for NM_000527.5(LDLR):c.1003G>C (p.Gly335Arg)]

NM_000527.5(LDLR):c.1003G>C (p.Gly335Arg)

Gene:
LDLR:low density lipoprotein receptor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
19p13.2
Genomic location:
Preferred name:
NM_000527.5(LDLR):c.1003G>C (p.Gly335Arg)
Other names:
NM_000527.5(LDLR):c.1003G>C; p.Gly335Arg
HGVS:
  • NC_000019.10:g.11110714G>C
  • NG_009060.1:g.26334G>C
  • NM_000527.5:c.1003G>CMANE SELECT
  • NM_001195798.2:c.1003G>C
  • NM_001195799.2:c.880G>C
  • NM_001195800.2:c.499G>C
  • NM_001195803.2:c.622G>C
  • NP_000518.1:p.Gly335Arg
  • NP_001182727.1:p.Gly335Arg
  • NP_001182728.1:p.Gly294Arg
  • NP_001182729.1:p.Gly167Arg
  • NP_001182732.1:p.Gly208Arg
  • LRG_274t1:c.1003G>C
  • LRG_274:g.26334G>C
  • NC_000019.9:g.11221390G>C
  • NC_000019.9:g.11221390G>C
  • NM_000527.4:c.1003G>C
Protein change:
G167R
Links:
dbSNP: rs544453230
NCBI 1000 Genomes Browser:
rs544453230
Molecular consequence:
  • NM_000527.5:c.1003G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195798.2:c.1003G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195799.2:c.880G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195800.2:c.499G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195803.2:c.622G>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hypercholesterolemia, familial, 1
Synonyms:
LDL RECEPTOR DISORDER; Hyperlipoproteinemia Type IIa; HYPER-LOW-DENSITY-LIPOPROTEINEMIA; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0007750; MedGen: C0745103; Orphanet: 391665; OMIM: 143890

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV004022374ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel
reviewed by expert panel

(ClinGen FH ACMG Specifications v1-2)
Uncertain significance
(Apr 28, 2023)
germlinecuration

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedcuration

Details of each submission

From ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel, SCV004022374.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcurationnot provided

Description

The NM_000527.4(LDLR):c.1003G>C (p.(Gly335Arg) variant is classified as Uncertain significance - insufficient evidence for Familial Hypercholesterolemia by applying evidence codes PM2 and PP3 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: - PM2 : PopMax MAF = 0.000008813 (0.0009%) in European non-Finnish exomes (gnomAD v2.1.1). It is below 0.02%, so PM2 is met. - PP3 : REVEL = 0.901. It is above 0.75, so PP3 is met.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024